Coronary dissection at site of recent BRS deployment: A case for the comeback kid?

Abstract

The Absorb bioresorbable scaffold (BRS) (Abbott vascular, Temecula, CA) is a fully resorbable intra-coronary device made of semi-crystalline poly-l-lactide (PLLA) that releases the anti-proliferative drug everolimus [1]. Pathologic and in vivo studies have reported the occurrence of neoatherosclerosis (NA) on lesions previously treated with drug-eluting stents (DES) or bare metal stent (BMS) [2]. To this day, there is no report on early NA in BRS-treated patients. We present the case of a coronary dissection in a segment recently treated with BRS implantation.